The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)].

Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA3 Jun 2004Cited by 113 (Europe PMC)

PMID15175844DOI10.1007/s00198-004-1636-zPepBankPUB-15175844

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men after teriparatide withdrawal, immediate bisphosphonate was linked to greater spine BMD change than no medication.
In plain wordsIn men after teriparatide withdrawal, immediate bisphosphonate was linked to better spine bone density change than no medication.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with immediate bisphosphonate versus no medication
Study
n = 21
Comparator
No medication after teriparatide withdrawal
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD increase
5.1%
immediate bisphosphonate group, 1 year
Lumbar spine BMD decline
3.7%
no medication group, 1 year
Source sentences
Summary
At the end of 1 year lumbar spine bone density increased an additional 5.1+/-1.0% in the bisphosphonate group, while it declined by 3.7+/-1.7% in those on no medication (P<0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584403
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men, lumbar spine BMD increased 5.1% with immediate bisphosphonate after teriparatide withdrawal.
In plain wordsIn men, spine bone density increased with immediate bisphosphonate after teriparatide withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with immediate bisphosphonate at one year
Study
n = 12
Comparator
Post-teriparatide baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD increase
5.1%
immediate bisphosphonate group, 1 year after teriparatide withdrawal
Source sentences
Summary
At the end of 1 year lumbar spine bone density increased an additional 5.1+/-1.0% in the bisphosphonate group, while it declined by 3.7+/-1.7% in those on no medication (P<0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584401
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men receiving immediate bisphosphonate for two years after teriparatide, spine BMD increased 8.9% above post-teriparatide values.
In plain wordsIn men, spine bone density increased with two years of immediate bisphosphonate after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with immediate bisphosphonate at two years
Study
n = 12
Comparator
Post-teriparatide baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD gain above post-teriparatide values
8.9%
immediate bisphosphonate group, 2-year post-teriparatide period
Source sentences
Summary
In contrast, the 12 men who began bisphosphonates immediately and continued treatment for the entire 2-year post-PTH period had continued gains at the lumbar spine, 8.9+/-1.5% above their post-PTH values (P=0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584406
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men, two years of teriparatide followed by two years of bisphosphonate yielded total spine BMD gains of 23.6%.
In plain wordsIn men, spine bone density increased over teriparatide followed by immediate bisphosphonate treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCumulative lumbar spine BMD with immediate bisphosphonate sequence
Study
n = 12
Comparator
Pretreatment baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total lumbar spine BMD gain
23.6%
2 years teriparatide plus 2 years bisphosphonate, 4-year period
Source sentences
Summary
For the 4-year period, including 2 years of teriparatide and 2 years of bisphosphonate, the total gains at the lumbar spine were 23.6+/-2.9%.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584407
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men without medication after teriparatide withdrawal, lumbar spine BMD declined 3.7% at one year.
In plain wordsIn men without medication after teriparatide withdrawal, spine bone density decreased.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseLumbar spine BMD without treatment at one year
Study
n = 9
Comparator
Post-teriparatide baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD decline
3.7%
no medication group, 1 year after teriparatide withdrawal
Source sentences
Summary
At the end of 1 year lumbar spine bone density increased an additional 5.1+/-1.0% in the bisphosphonate group, while it declined by 3.7+/-1.7% in those on no medication (P<0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584402
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men delaying bisphosphonate until one year after teriparatide withdrawal, spine BMD gained 2.6% during the second year.
In plain wordsIn men, spine bone density increased during delayed bisphosphonate treatment after teriparatide withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD with delayed bisphosphonate
Study
n = 6
Comparator
Start of delayed bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Measurements
Lumbar spine BMD gain in second year
2.6%
delayed bisphosphonate group (6 men)
Source sentences
Summary
In six men who delayed initiation of bisphosphonate until 1 year after teriparatide withdrawal, their subsequent gains in the second year, 2.6+/-1.7%, still placed them below the peak gains they achieved on teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584404
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men receiving bisphosphonate only in the second year after teriparatide withdrawal, cumulative spine BMD gains were 11.1%.
In plain wordsIn men, spine bone density increased over teriparatide followed by delayed bisphosphonate treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCumulative lumbar spine BMD with delayed bisphosphonate sequence
Study
n = 6
Comparator
Pretreatment baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Cumulative lumbar spine BMD gain
11.1%
bisphosphonate in 2nd year only
Source sentences
Summary
Men, who received bisphosphonate in only the 2nd year post-teriparatide, had cumulative gains of 11.1+/-3.4%.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584408
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In men receiving no bisphosphonate after teriparatide withdrawal, cumulative spine BMD gains were 5.5%.
In plain wordsIn men, cumulative spine bone density remained above pretreatment baseline without bisphosphonate after teriparatide withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCumulative lumbar spine BMD without post-teriparatide bisphosphonate
Study
n = 3
Comparator
Pretreatment baseline
Outcome group
Bone and joint · Musculoskeletal
Measurements
Cumulative lumbar spine BMD gain
5.5%
no bisphosphonate in post-PTH period (3 men)
Source sentences
Summary
Three men who did not receive any bisphosphonate at any time during the post-PTH period had cumulative gains of only 5.5+/-3.7%.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 21 men for up to 2 years after discontinuing teriparatide.
Summary · context
Twelve men (57%) chose treatment with bisphosphonate immediately after teriparatide withdrawal, while 9 (43%) opted for no pharmacologic agent.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1517584409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.